Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular events in maintenance hemodialysis patients by HASEGAWA Ayako et al.
Triglyceride to high-density lipoprotein
cholesterol ratio predicts cardiovascular
events in maintenance hemodialysis patients
journal or
publication title
Renal Replacement Therapy
volume 2
page range 60
year 2016-11-10
URL http://doi.org/10.20780/00031633
doi: https://doi.org/10.1186/s41100-016-0069-4
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
Hasegawa et al. Renal Replacement Therapy  (2016) 2:60 
DOI 10.1186/s41100-016-0069-4RESEARCH Open AccessTriglyceride to high-density lipoprotein
cholesterol ratio predicts cardiovascular
events in maintenance hemodialysis
patients
Ayako Hasegawa1, Fumiko Kojima1, Mio Ueda1, Yoshiko Tanaka1 and Kosaku Nitta2*Abstract
Background: The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio has been shown to be a
predictor of cardiovascular (CV) outcomes in the general population. The aim of this study was to determine whether
the TG/HDL-C ratio is a predictor of CV events and all-cause mortality in maintenance hemodialysis (MHD) patients.
Methods: We performed a retrospective, observational cohort study in which we enrolled 193 MHD patients from a
single center in Japan who had been followed up for a median of 3.9 years. The outcomes were the occurrence of a
CV event and all-cause mortality during the follow-up period. Baseline TG/HDL-C ratios were investigated for
associations with outcomes by using Cox regression models adjusted for demographic parameters.
Results: Overall, 88 of the subjects experienced a CV event, and 32 patients had died, of whom 4 died due to CV
events. Patients with higher TG/HDL-C levels (tertile 3) had a higher incidence of CV events (adjusted hazard ratio [HR]
1.82, 95 % confidence interval [CI] 1.01–3.35) and higher all-cause mortality (adjusted HR 6.13, 95 % CI 2.13–20.22) than
the patients in tertile 1. Kaplan–Meier analyses by the log-rank test showed that the TG/HDL-C ratio had significant
predictive power for detecting a CV event.
Conclusions: The TG/HDL-C ratio is a reliable and easily accessible marker for predicting CV events and mortality in
MHD patients.
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Chronic kidney disease (CKD) is one of the major causes
of dyslipidemia [1], and an elevated serum triglyceride
(TG) level is a common feature of CKD [2]. The serum
concentrations of TG-rich lipoproteins, including very-
low-density lipoprotein, start to increase in the early
stages of CKD. The predominant mechanism responsible
for the increased concentration of TG-rich lipoproteins
in CKD is a low catabolic rate [3]. By contrast, several
epidemiological studies have demonstrated that high-
density lipoprotein cholesterol (HDL-C) is a negative
risk factor for atherosclerosis [4].* Correspondence: knitta@kc.twmu.ac.jp
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(http://creativecommons.org/publicdomain/zeDyslipidemia in which there is a combination of a high
TG level and low HDL-C level has been reported to
strongly predict cardiovascular (CV) morbidity, and coron-
ary artery disease, in particular, in the general population
[5, 6]. Several studies have demonstrated a correlation be-
tween the TG to HDL-C (TG/HDL-C) ratios and both the
severity of insulin resistance and presence of coronary ath-
erosclerotic lesions in the general population [7, 8]. The
TG/HDL-C ratio has been shown to predict the occurrence
of myocardial infarction, ischemic heart disease [9, 10], and
CV mortality, both in women with coronary artery disease
and in the general population [11, 12].
Low-density lipoprotein cholesterol (LDL-C) has been
found to be a non-sensitive marker for risk of CV events
because of its weak association with coronary events in
CKD patients who have a low estimated glomerularle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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has been clearly demonstrated in response to aggressive
LDL-C reduction strategies [15, 16]. Hypertriglyceridemia
has been reported to have a U-shaped relationship with
mortality in HD patients [17, 18], whereas HDL-C has
been reported to have a discordant association with all-
cause or CV mortality in HD patients [19, 20].
The aim of this study was to determine if the TG/
HDL-C ratio is a predictor of CV events and all-cause
mortality in maintenance HD (MHD) patients.
Methods
Subjects
This was a retrospective cohort study conducted at a single
center in Japan. The subjects were recruited from among
patients who had been routinely dialyzed via an arterioven-
ous fistula in the dialysis unit of the Shinjuku Ishikawa
Clinic for at least 6 months by the procedure [21].
MHD patients with malignancy, active inflammation,
liver cirrhosis, gastrointestinal bleeding, or severe illness
were excluded from participation as subjects. The pa-
tients who were enrolled as subjects (n = 193) had been
undergoing stable regular HD with a bicarbonate dialys-
ate. The underlying disease was chronic glomeruloneph-
ritis in 85 cases, diabetic nephropathy in 68 cases,
hypertensive nephrosclerosis in 30 cases, polycystic kid-
ney disease in 8 cases, and chronic pyelonephritis in 2
cases.
Evaluation of demographic and laboratory parameters
All patients were on thrice-weekly HD therapy. Blood
pressure (BP) was measured with a mercury sphygmo-
manometer with the patient in the supine position after
resting for 10 to 15 min, and mean values for the 1-
month period preceding enrollment were used in the
statistical analysis. Dry weight was targeted to achieve a
normotensive edema-free state. Information regarding
previous CV disease was collected from the patient’s
medical records. Diabetes mellitus (DM) was recorded
as present if the patient had been diagnosed with DM
and/or had a fasting plasma glucose concentration
>126 mg/dl or HbA1c value >6.5 % or prescription of
glucose-lowering agent.
A past history of CV disease was recorded as positive
if the patient had a history of stroke, coronary artery dis-
ease (including myocardial infarction and unstable an-
gina), or history of decompensated heart failure. Body
mass index (BMI) was calculated by dividing body
weight in kilograms by body height in meters squared
and is expressed in kg/m2.
Blood samples were collected before dialysis sessions
after an overnight fast. Whole blood samples were used
to measure hemoglobin, and serum samples were used
to measure creatinine, albumin, calcium, phosphorus,TG, total cholesterol (T-Chol), LDL-C, HDL-C levels,
and C-reactive protein (CRP) levels with an autoanalyzer
(Hitachi Co., Tokyo, Japan) that uses standard laboratory
methods. Whole parathyroid hormone (PTH) levels were
determined by immunoassay [22].
Outcomes
Primary outcomes were a CV event, which was recorded as
having occurred when a new CV event, including a coron-
ary event (nonfatal myocardial infarction, unstable angina,
and coronary revascularization) was diagnosed, a patient
was hospitalized for heart failure, a patient was hospitalized
for incident stroke (either ischemic or hemorrhagic stroke),
or an incident peripheral arterial disease requiring surgical
intervention was diagnosed. The secondary outcome was
all-cause mortality. The outcome information was centrally
adjudicated by trained nephrologists based on the above
prespecified criteria.
Statistical analysis
Continuous data are reported as the mean value ±
SD, and categorical data are reported as percentages.
Differences in baseline characteristics and biochemical
parameters were assessed using Student’s t test and
the Mann–Whitney U test. Groups of patients in dif-
ferent TG/HDL-C ratio tertiles were compared in re-
gard to continuous variables by analysis of variance,
and in regard to nonnormally distributed continuous
variables by the nonparametric Kruskal–Wallis test,
and the χ2 test was used for categorical variables. To
evaluate and compare the predictive performance of
the TG/HDL-C ratio and non-HDL-C levels, we used
receiver operating characteristic (ROC) curves for
censored data and the area under the ROC curve
(AUC) as the criterion.
We stratified the patients into three groups according
to their TG/HDL-C ratio. The primary predictor variable
was the TG/HDL-C ratio in each tertile. The outcome
analysis was performed by using Cox proportional haz-
ard models. We considered some variables whose P
value was <0.10 according to the results of the univariate
logistic regression analyses in the multivariate analysis.
The adjusted covariates included age, gender, dialysis
vintage, presence of DM, previous CV disease, CRP, cre-
atinine, statin use and hemoglobin levels in the analysis
of a CV event, and all-cause mortality. The results are
expressed as hazard ratios (HRs) and 95 % confidence
intervals (CIs). The age- and gender-related odds ratios
(ORs) for CV events and all-cause mortality were calcu-
lated using logistic regression models. We also selected
the non-HDL-C value (calculated by subtracting the
HDL-C value from the T-Chol value) [23] and stratified
the patients into tertiles accordingly for analysis. We
tested for heterogeneity in the relationship between
Table 1 Baseline characteristics of the study subjects according to the TG/HDL-C ratio
All patients TG/HDL-C tertile 1
(0.35–1.60)
n = 64
TG/HDL-C tertile 2
(1.61–3.00)
n = 65
TG/HDL-C tertile 3
(3.01–64.05)
n = 64
P value
Age, years 60 (50–69) 59 (51–68) 61 (51–70) 57 (49–65) 0.3249
Female sex, % 26.8 28.2 28.2 24.1 0.7819
DM, % 32.3 28.2 31.8 36.8 0.4837
Dialysis vintage, years 9.4 (4.7–15.8) 11.1 (5.7–16.3) 10.8 (4.4–16.9) 8.0 (4.6–13.8) 0.2608
History of hypertension, % 79.7 80.0 76.5 82.6 0.6107
History of previous CVD, % 29.2 23.5 35.3 28.7 0.2394
Systolic BP, mmHg 153 (139–165) 154 (142–165) 152 (138–166) 153 (136–163) 0.7112
Diastolic BP, mmHg 82 (73–91) 83 (76–91) 81 (72–90) 82 (70–93) 0.4152
BMI, kg/m2 21.8 (19.7–24.4) 20.5 (19.0–22.6) 21.8 (19.7–24.0) 23.2 (21.1–25.7) <0.0001
Laboratory data
Hemoglobin, g/dL 10.7 (10.2–11.2) 10.7 (10.2–11.1) 10.6 (10.1–11.2) 10.8 (10.1–11.4) 0.2499
Creatinine, mg/dL 11.8 (10.3–13.5) 11.4 (10.15–12.75) 12.0 (10.15–13.65) 12.3 (10.4–13.9) 0.1032
Calcium (Ca), mg/dL; corrected 9.0 (8.6–9.4) 9.0 (8.6–9.4) 9.1 (8.45–9.4) 9.0 (8.6–9.4) 0.9831
Phosphorus (P), mg/dL 5.4 (4.6–6.1) 5.5 (4.8–6.2) 5.1 (4.4–5.9) 5.5 (4.5–6.1) 0.0967
Ca x P, (mg/dL)2 48.1 (40.9–55.2) 51.4 (42.1–55.7) 45.6 (40–54.1) 47.8 (41.2–57) 0.0554
Whole PTH, pg/mL 63 (31–103) 68 (28–95) 53 (27–110) 64 (34–114) 0.5728
CRP, mg/L 0.1 (0.1–0.3) 0.1 (0.1–0.2) 0.1 (0.1–0.3) 0.1 (0.1–0.4) 0.1403
Albumin, g/L 3.9 (3.7–4.1) 3.9 (3.7–4.1) 3.9 (3.7–4.1) 3.9 (3.7–4.1) 0.9530
T-CHO, mg/dL 157 (137–178) 156 (136–177) 150 (133–170) 162 (142–188) 0.0341
TG, mg/dL 98 (70–144) 60 (47–73) 98 (83–112) 172 (138–229) <0.0001
HDL-C, md/dL 44 (37–55) 59 (51–72) 43 (40–49) 37 (31–41) <0.0001
LDL-C, mg/dL 77 (62–94) 69 (54–86) 79 (65–103) 86 (64–105) 0.0001
TG/HDL-C ratio 2.28 (1.29–3.66) 1.03 (0.76–1.29) 2.27 (1.84–2.61) 4.63 (3.62–6.57) <0.0001
Medications, %
ESA 92.5 91.5 90.5 95.4 0.4447
HMG-CoA reductase inhibitors 29.4 22.9 24.7 40.5 0.0228
Antihypertensive agents 79.0 77.7 78.8 80.5 0.9017
DM diabetes mellitus, CVD cardiovascular disease, BP blood pressure, BMI body mass index, PTH parathyroid hormone, CRP C-reactive protein, T-Chol total choles-
terol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density cholesterol, ESAs erythropoiesis-stimulating agents
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Fig. 1 ROC curve of the TG/HDL-C ratios and non-HDL-C levels as predictors of the outcomes. The TG/HDL-C ratio exhibited a similar predictive
performance for cardiovascular events and all-cause mortality
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Table 2 Hazard ratios (HRs) of dyslipidemia in predicting the
outcomes using Cox proportional hazards regression models
with multivariate adjustments
CV event
Adjusted HR
(95 % CI)
All-cause mortality
Adjusted HR
(95 % CI)
TG/HDL-C ratio
TG/HDL-C ratio tertile
(Third vs first tertile) 1.82 (1.01–3.35) 6.13 (2.13–20.22)
TG/HDL-C ratio tertile
(Second vs first tertile) 1.84 (1.05–3.31) 2.64 (0.92–8.38)
TG/HDL-C ratio >1.64
(yes vs no)
1.81 (1.11–3.06) 3.12 (1.30–8.54)
Non-HDL-C
Non-HDL-C tertile
(Third vs first tertile) 1.19 (0.71–2.01) 1.32 (0.55–3.20)
Non-HDL-C quartile
(Second vs first tertile) 0.90 (0.32–2.37) 1.47 (0.49–4.29)
Non-HDL-C >140 mg/dL
(yes vs no)
1.51 (0.88–2.51) 1.56 (0.53–4.09)
Adjusted for age, sex, dialysis vintage, presence of DM, concurrent CV disease,
CRP, creatinine, statin use, and hemoglobin levels
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Fig. 2 Kaplan–Meier curves for patients with different TG/HDL-C ratio level
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our statistical model as previously described [24]. The
survival analysis was based on the Kaplan–Meier curve
with subjects censored for death. A log-rank test was
used to compare the survival rates of two groups. P
values <0.05 were considered evidence of statistical sig-
nificance. All statistical analyses were performed by
using the SAS version 9.2 software program (SAS Insti-
tute Inc., Cary, NC, USA) for Windows.
Results
The baseline characteristics of the subjects according to
TG/HDL-C tertiles are summarized in Table 1. The study
cohort consisted of 193 subjects, 52 females, and 141
males, and their mean age was 59.3 ± 12.7 years. Their
mean dialysis vintage was 11.0 ± 7.7 years, and their mean
BMI was 22.3 ± 3.7 kg/m2. All of the subjects had an ar-
teriovenous fistula. None of the subjects had residual renal
function (urine volume >100 mL/day). DM was present in
32.3 %. A history of CVD was present in 29.2 %.
The patients in the TG/HDL-C tertiles had different
levels of BMI and lipid profiles. There was no signifi-
cant difference between the median values of TG/
HDL-C ratio were 2.28 at the time of entry and 2.31
after 1 month and 2.22 after 2 months. The TG/HDL-30 40 50
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Fig. 3 Kaplan–Meier curves of patients with different non-HDL-C levels. a Cardiovascular events. b All-cause mortality
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(29.4 %) was significantly higher than those (2.83 ±
3.09) in subjects without statin treatment (70.6 %)
(P = 0.0028).
During the mean follow-up period of 43.3 ± 11.0 months,
88 of the subjects experienced a CV event, and 32 patients
died, 4 of a CV event. Among the 88 patients who experi-
enced a CV event, 17 had an intracranial hemorrhage or
ischemic stroke, 33 had coronary artery disease (either
nonfatal acute myocardial infarction or coronary revascu-
larization or coronary bypass surgery), 11 had peripheral
arterial disease, 16 were hospitalized for heart failure, and
the CV events in the other subjects were unknown. Of the
32 patients who died of any cause, 11 died of an infectious
disease, 6 of a sudden cardiac death, 5 of malignancy, and
4 of a cerebrovascular event, and the causes of other death
were unknown.
The AUCs for the TG/HDL-C ratio and non-HDL-C
level vs. outcomes are shown in Fig. 1. The TG/HDL-C
ratio and non-HDL-C levels exhibited similar predictive
performance for CV event outcome (AUC 0.583 vs.
AUC 0.543, P = 0.2859) and all-cause mortality outcome
(AUC 0.591 vs. AUC 0.536, P = 0.3455).In the multivariate Cox regression model, the MHD
patients with a higher TG/HDL-C level (tertile 3; T3)
had a higher incidence of CV events (adjusted HR 1.82,
95 % CI 1.01–3.35) and higher all-cause mortality (ad-
justed HR 6.13, 95 % CI 2.13–20.22) than the patients in
tertile 1 (T1, Table 2). When the TG/HDL-C ratio was
used as a dichotomous variable, the group with a TG/
HDL-C ratio >1.64 was found to have a higher incidence
of CV events (adjusted HR 1.81, 95 % CI 1.11–3.06).
Similarly, the group in non-HDL-C tertile 3 also had a
higher incidence of CV events and all-cause mortality
than the group in non-HDL-C tertile 1. In addition, the
group with a TG/HDL-C ratio >1.64 was found to have
a higher incidence of cerebrovascular events, although
not significant (adjusted HR 2.66, 95 % CI 0.85–3.14).
The Kaplan–Meier survival estimates of CV events and
all-cause mortality at different TG/HDL-C ratios are shown
in Figs. 2 and 3. The results of the log-rank test showed
that the TG/HDL-C ratio had significant predictive power
for detecting the CV events (Fig. 2a, P = 0.0392). However,
the TG/HDL-C ratio did not significantly significant con-
tribute to predicting all-cause mortality (Fig. 2b,
P = 0.1543). As shown in Fig. 3a, b, there was no significant
Hasegawa et al. Renal Replacement Therapy  (2016) 2:60 Page 6 of 8difference in non-HDL-C level tertiles for predicting CV
events (P = 0.0631) and all-cause mortality (P = 0.3442).
Stratified analyses to detect associations between TG/
HDL-C ratios and CV events and all-cause mortality ac-
cording to gender and presence of DM revealed that the
risk of a CV event gradually increased with greater TG-
HDL-C ratios (P = 0.0076 for interaction, Fig. 4a). How-
ever, the risk of all-cause mortality was not associated
with greater TG-HDL-C ratios (Fig. 4b).Discussion
The results of this study showed that the baseline TG/
HDL-C ratio was predictive of CV events and all-cause
mortality in MHD patients. Dyslipidemia in MHD pa-
tients with the TG/HDL-C ratio for stratification of its
severity should be recognized as a reliable and readily
available tool for predicting long-term CV outcomes and
survival.Female
Male
Diabetes (-)
Diabetes (+)
b
a
Female
Male
Diabetes (-)
Diabetes (+)
Fig. 4 Odds ratio for CV events (a) and all-cause mortality (b) according to
diabetes mellitusHD patients have unique lipid profiles, and the associa-
tions between their lipid profiles and CV outcomes and
mortality are different from the associations in the general
population [17]. Several clinical studies of dialysis patients
have reported finding unique correlations between the
levels of T-CHO and LDL-C levels and CV outcomes, the
so-called “cholesterol paradox” [25, 26]. In addition, recent
data have shown the absence of a significant association
between the HDL-C levels and their risk of CV events of
diabetic HD patients [20], and HDL-C and TG did not to
predict CV or all-cause mortality in a large HD cohort
who were followed up for 3 years [17]. The non-HDL-C
level is also easily calculated by subtracting the HDL-C
from TC, and non-HDL levels have been found to be a
predictor of CV outcomes in MHD patients [27, 28]. The
TG/HDL ratio was superior to the non-HDL-C as a pre-
dictor of CV event in the present study (Table 2).
We used the TG/HDL-C ratio to predict CV events
and all-cause mortality in MHD patients in the presentP for
trend
P for
interaction
0.0152
0.6595
0.1410
0.4707
0.7997
0.2894
P for
trend
P for
interaction
0.2852
0.0783
0.1180
0.3183
0.0076
0.4331
tertile (T) of TG/HDL-C ratio stratified by gender and presence of
Hasegawa et al. Renal Replacement Therapy  (2016) 2:60 Page 7 of 8study, and the results clearly demonstrated the predict-
ive power of the TG/HDL-C ratio. Chen et al. have re-
cently shown the predictive ability of the TG/HDL-C
ratio for CV outcomes and survival in patients undergo-
ing prevalent dialysis [29]. The TG/HDL-C ratio may
therefore be the optimal marker for predicting CV out-
comes in MHD patients. Moreover, a higher TG/HDL-C
ratio including atherogenic lipoprotein particles results
in consequent CV events in MHD patients [30].
The cut-off value of TG/HDL-C ratio in prediction of
CV event in our study was much lower than that in the
previous studies [29, 31]. One of the reasons for lower
TG/HDL-C ratio of our patients seems to be based on
the good management of food intake by dietitian. In
addition, most of the patients came to our dialysis clinic
without assistance on foot. Moreover, we could not rule
out the effects of statin treatment. The TG/HDL-C ratio
(5.02 ± 8.57) in subjects with statin was significantly
higher than those (2.83 ± 3.09) in subjects without statin
(P = 0.0028), suggesting that statin had been adminis-
tered to patients with increased serum TG.
The mechanisms underlying the association between
TG/HDL-C ratios and CV event and all-cause mortality
in MHD patients are still unknown. A previous study
showed significant associations between increases in
TG/HDL ratio and both decreases in LDL particle size
and increases in fractional esterification rates of choles-
terol in plasma depleted of apoB lipoproteins [32].
Moreover, the TG/HDL-C ratio is already been used as a
predictor of insulin resistance [33] and DM [34]. Insulin
resistance has been found to increase the serum concen-
trations of TGs and HDL-C, and the TG/HDL-C ratio
was involved in decreased insulin secretion and poor
glycemic control among subjects with type 2 DM [35].
We found an interaction between the TG/HDL-C ratio
and DM in the prediction of CV events (Fig. 4a). This
finding is consistent with the interaction between them in
predicting events in the general population, and patients
with a high TG/HDL-C ratio have been reported to be
predisposed to DM [36]. The diabetic status of patients
with both DM and dyslipidemia is crucial when assessing
CV outcomes compared with non-diabetic patients with
dyslipidemia. As shown in a clinical study [37], manipula-
tion of high TG and low HDL-C levels in DM patients by
medical interventions does not reduce their risk of CV
outcomes. Consequently, the utility of the TG/HDL-C ra-
tio for predicting long-term CV outcomes in diabetic
MHD patients should be carefully assessed in further
large-scale investigations.
The present study had several limitations. First, the ob-
servational nature of the study precludes drawing conclu-
sions about causal relationships. Second, we did not
measure the specific lipoproteins related to atherogenic
dyslipidemia, such as apolipoprotein B, which may be morespecific to LDL particles, and the relationship between TG/
HDL-C ratios and apolipoproteins in MHD patients needs
to be validated further. Third, the AUC for TG/HDL-C ra-
tio was 0.583, implying a low accuracy (<0.7). Fourth, this
was a single-center study; all of the participants were Japa-
nese and treated by the same physicians, and the same uni-
form laboratory tests were performed during the
observation period, which guaranteed the accuracy of our
results, but our conclusions cannot be generalized to other
ethnicities.
Conclusions
The results of this study suggest that the TG/HDL-C ra-
tio can independently predict CV events and mortality
in MHD patients, especially in diabetic MHD patients.
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